Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, First in Human, Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Triple-specific T-cell Engager 1A46 in Adult Patients with Advanced CD20 And/or CD19 Positive B-cell Hematologic Malignancies

NCT05348889 is registered in ClinicalTrials.gov with Chimagen Biosciences, Ltd as lead sponsor.

NCT NCT05348889
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05348889 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, First in Human, Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Triple-specific T-cell Engager 1A46 in Adult Patients with Advanced CD20 And/or CD19 Positive B-cell Hematologic Malignancies
Lead sponsor
Chimagen Biosciences, Ltd
Phase
Phase 1/2
Overall status
Terminated
Start date
August 30, 2022
Completion date
October 31, 2024
Enrollment
7 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoid leukemia, disease (disorder), non-hodgkin's lymphoma (disorder)